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Abstract 
Background: Malaria is one of the most prevalent tropical infectious diseases. Since recently cases of artemisinin 
resistance were reported, novel anti-malarial drugs are required which differ from artemisinins in structure and bio-
logical target. The plasmodial glycogen synthase kinase-3 (PfGSK-3) was suggested as a new anti-malarial drug target. 
4-Phenylthieno[2,3-b]pyridines were previously identified as selective PfGSK-3 inhibitors with antiplasmodial activity. 
The present study aims at identifying a molecular position on this scaffold for the attachment of side chains in order 
to improve solubility and antiplasmodial activity. Furthermore, the role of axial chirality in the compound class for 
antiplasmodial activity and PfGSK-3 inhibition was investigated.
Methods: 4-Phenylthieno[2,3-b]pyridines with substituents in 4-position of the phenyl ring were docked into the 
ATP binding site of PfGSK-3. The compounds were synthesized employing a Thorpe reaction as final step. The enantio-
mers of one congener were separated by chiral HPLC. All derivatives were tested for inhibition of asexual erythrocytic 
stages of transgenic NF54-luc Plasmodium falciparum. Selected compounds with promising antiplasmodial activity 
were further evaluated for inhibition of HEK293 cells as well as inhibition of isolated PfGSK-3 and HsGSK-3. The kinetic 
aqueous solubility was assessed by laser nephelometry.
Results: The para position at the 4-phenyl ring of the title compounds was identified as a suitable point for the 
attachment of side chains. While alkoxy substituents in this position led to decreased antiplasmodial activity, 
alkylamino groups retained antiparasitic potency. The most promising of these congeners (4h) was investigated in 
detail. This compound is a selective PfGSK-3 inhibitor (versus the human GSK-3 orthologue), and exhibits improved 
antiplasmodial activity in vitro as well as better solubility in aqueous media than its unsubstituted parent structure. 
The derivative 4b was separated into the atropisomers, and it was shown that the (+)-enantiomer acts as eutomer.
Conclusions: The attachment of alkylamino side chains leads to the improvement of antiplasmodial activity and 
aqueous solubility of selective PfGSK-inhibitors belonging to the class of 4-phenylthieno[2,3-b]pyridines. These 
molecules show axial chirality, a feature of high impact for biological activity. The findings can be exploited for the 
development of improved selective PfGSK-3 inhibitors.
Keywords: Anti-malarial drugs, Atropisomers, Axial chirality, Drug discovery, Malaria, PfGSK-3, Plasmodium falciparum, 
Protein kinase, Thienopyridines, Thorpe cyclization
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Background
In spite of successful efforts to fight malaria in recent 
years, the infection remains one of the most widespread 
 and dangerous tropical diseases. As a result of improved 
diagnosis, intensified vector control and infection 
prophylaxis, the prevalence of malaria significantly 
declined between the years 2000 and 2015 in terms of 
both morbidity and mortality. This positive develop-
ment recently came to a standstill in 2016. 216 million 
cases were reported globally, an increase of five million 
cases over the count in the previous year. Furthermore, 
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the rate of fatalities resulting from the infection is no 
longer decreasing, but stagnating at approximately 
440,000 per year [1]. The most lethal form of the dis-
ease is caused by the parasite Plasmodium falciparum. 
Artemisinin-based combination therapy (ACT) is 
recommended for the treatment of P. falciparum malaria 
[1]. Unfortunately, resistant P. falciparum strains have 
been reported against all deployed anti-malarial drugs, 
including artemisinins. Artemisinin resistance was ini-
tially observed in South-East Asia [2] and is currently still 
restricted to this geographic area [3]. However, spread 
of artemisinin resistance to other parts of the world, 
especially sub-Saharan Africa (where most of the P. fal-
ciparum infections occur), would create a desperate situ-
ation [4]. Novel drugs for prophylaxis and treatment of 
malaria are urgently required, either as replacement or 
additional partner for artemisinin-based combinations. 
To prevent cross-resistance, new medicines should have 
an untapped mode of action, and therefore be based on 
chemotypes distinct from artemisinins or other estab-
lished anti-malarial drugs [5].
Plasmodial kinases have consistently been suggested 
as biological targets for anti-malarial drugs [6–13], and 
a number of medicinal chemistry campaigns have been 
performed to develop kinase inhibitors as antiplas-
modial compounds [14]. MMV390048 was identified 
from a phenotypic screening campaign. The compound 
inhibits the Plasmodium phosphatidylinositol 4-kinase 
(PfPI4K) [15] and is currently in clinical trials as an anti-
malarial drug [14]. The kinome of P. falciparum includes 
65 kinases related to the eukaryotic protein kinase fam-
ily, of which 36 were found to be essential for the eryth-
rocytic schizogony. Among these essential kinases is 
the plasmodial glycogen synthase kinase-3 (PfGSK-3), 
the orthologue of the human serine/threonine kinase 
GSK-3 [16]. As an important link in the signaling path-
way downstream of the insulin receptor, HsGSK-3 deac-
tivates glycogen synthase (GS) by phosphorylation. The 
kinase is also an intracellular part of the Wnt pathway 
which regulates cell fate during embryonic development 
[17]. Because several human diseases are connected to 
hyperactivity of GSK-3 (e.g. Alzheimer’s disease, diabe-
tes and cancer), a variety of GSK-3 inhibitors were devel-
oped as potential drugs [18]. The manifold roles of GSK-3 
in mammalian organisms led to speculations about the 
function of PfGSK-3 in the parasite, e.g. regulation of the 
cell cycle, cellular differentiation, and metabolism [19, 
20]. The plasmodial gene homologue PfGSK-3 of mam-
malian GSK-3 was identified and cloned by PCR [19]. The 
sequence characterization of PfGSK-3 and the compari-
son with the human orthologue revealed a considerable 
degree of similarity within the catalytic domain. Impor-
tant amino acids of the active site of HsGSK-3 (Lys85, 
Glu97, Asp181 and Asp200) are conserved in PfGSK-3 
(as Lys108, Glu20, Asp206 and Asp225, respectively). A 
main difference between the two proteins is the lack of 
a phosphorylation site in PfGSK-3 analogous to Ser9 in 
HsGSK-3β. Once phosphorylated, the latter residue is 
responsible for HsGSK-3 auto-inhibition through bind-
ing to the P + 4 phosphate binding cleft present in the 
enzyme [21]. Furthermore, PfGSK-3 has an N-terminal 
extension which is not present in mammalian GSK-3 
[19]. Recently it has been shown that phosphorylation of 
the apical membrane antigen 1 (AMA1) of P. falciparum 
by PfGSK-3 is required for efficient invasion of red blood 
cells by merozoites [22]. Since PfGSK-3 appears to be 
essential, GSK-3 inhibitors were suggested as antiplasmo-
dial agents [19]. An initial study with a set of established 
GSK-3 inhibitors revealed that some of these chemo-
types (e.g. hymenialdisine and indirubin-3′-monoxime) 
do indeed affect PfGSK-3 activity, but do not distinguish 
between the plasmodial and the mammalian orthologue 
[19]. However, representatives of the paullone class of 
compounds [23, 24] exhibited a remarkable preference 
for inhibition of mammalian GSK-3, thus indicating that 
species selectivity may be achievable [19]. Based on this 
assumption, a high throughput screening was carried 
out by testing compound libraries against both PfGSK-
3, using the mammalian orthologue in a counter screen 
[25]. This produced a small number of hit compounds 
characterized by a thieno[2,3-b]pyridine parent scaffold, 
which displayed selectivity against the plasmodial (versus 
human) enzyme. Chemical modification of this scaffold 
identified compound 1 (Fig.  1), which selectively inhib-
ited PfGSK-3 in an ATP-competitive manner and showed 
antiparasitic activity on P. falciparum erythrocytic stages 
in vitro [25]. Further structure modification of 1 revealed 
rather narrow structure–activity relationships. For exam-
ple, the ortho-halogen substituent on the 4-phenyl ring 
was required for PfGSK-3 inhibition, replacement of the 
carbonyl linker by an amide function and annulation at 
positions 5,6 with cyclohexane led to decreased kinase 
inhibitory activity, and exchange of the benzoyl element 
for a nitrile group decreased selectivity [25].
An unfavourable feature of compound 1 and similar 
molecules is the poor solubility in aqueous media, a 
property of high relevance for the development of drugs 
intended for oral application. The poor solubility of 1 is 
probably caused only by high lipophilicity but may also 
be a consequence of a high insaturation count. Since 
not a single carbon atom in 1 is  sp3 hybridized, the 
fraction  sp3  (Fsp3 = number of  sp3 hybridized carbons/
total carbon count) is zero, a very unfavourable predic-
tor for drug likeness [26]. Improvement of solubility is 
possible by attachment of aliphatic polar side chains, 
which introduce both  sp3 hybridized carbons and polar 
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groups. However, such side chains can compromise 
biological activity of the compound if they interfere 
with the mode of binding to the biological target. In 
the present study, options for optimization of 1 towards 
antiplasmodial activity and aqueous solubility were 
investigated. In this regard, it was essential to identify a 
position at the molecular structure 1 where side chains 
are tolerated without loss of biological activity. For the 
reasons mentioned above it was important to consider 
the interaction mode of 1 and its congeners with the 
ATP binding pocket of PfGSK-3. While an X-ray struc-
ture of PfGSK-3 has not yet been published, homology 
models of PfGSK-3 are available which were generated 
based on HsGSK-3β X-ray structures with different co-
crystallized ligands [27]. A docking study utilizing such 
a homology model predicted the orientation of 1 in the 
PfGSK-3 binding site as illustrated in Fig. 2 [25]. In this 
model, the ortho halogen substituent is accommodated 
in a shallow cavity at the bottom of the ATP binding 
pocket. The substituents at 5- and 6-position of the par-
ent heterocycle build hydrogen bonds to the hinge area, 
and the carbonyl oxygen interacts with the conserved 
lysine (Lys108). The 4-phenyl substituent is directed 
towards the entrance to the ATP binding pocket, offer-
ing its para-position for attachment of additional sub-
stituents without hampering the fit to the binding 
pocket. With a view to challenge this model of inhibi-
tor-enzyme interaction, three series of congeners were 
synthesized and evaluated for antiplasmodial activity. 
The congeners carry either small substituents (halo-
gen, methyl, hydroxy; series 2), alkoxy groups (series 
3), or alkylamino substituents (series 4) in the desig-
nated para position of the 4-phenyl substituent (Fig. 1). 
In contrast to the target-oriented screening campaign 
that led to the prototype 1 reported earlier [25], in the 
present study a phenotypic assay was employed with 
a view to addressing pharmaceutical properties like 
membrane permeability in an early development stage. 
For the determination of antiplasmodial activity, the 
bioluminescence generated by transgenic NF54-luc P. 
falciparum erythrocytic stages in the presence of test 
compounds was assessed in a luciferase assay system 
[28]. The prototype compound 1 and the congeners 2–
4 display direct single bonds between the thieno[2,3-b]
pyridine and the phenyl substituent. Due to the ortho 
chloro-substitution of the phenyl residue the molecules 
show atropisomerism, and consequently one of the two 
atropisomers should display stronger biological activity. 
This hypothesis was corroborated by separation of an 
active racemic derivative and comparison of the result-
ing enantiomers regarding enzyme inhibition as well as 
antiplasmodial activity.
Methods
Molecular docking
A homology model of the PfGSK-3 [27] was used for 
molecular docking. Ligand molecular structures were 
generated and energy minimized using Molecular Oper-
ating Environment (MOE, 2013.08, Chemical Comput-
ing Group Inc., Montreal, Canada). Protein and ligand 
pdb files were saved as mol2 files and loaded utilizing 
the docking tool GOLD (version 5.2.2.) [30]. To direct 
Fig. 1 Left: Structures of the antiplasmodial selective PfGSK-3 inhibitor 1 [25] with indicated locants at the heterocyclic parent scaffold (right) and 
derivatives 2–4 with sidechains attached to the para position of the 4-phenyl ring as listed in Table 1
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the ligands to the ATP binding area, the ligand binding 
site was defined as a sphere with a radius of 10 Å around 
the gatekeeper amino acid (Met157). Chemscore [31] 
with kinase specific parameters implemented in GOLD 
was applied as scoring function. For the docking, two 
constraints based on the position of a thieno[2,3-b]pyri-
dine in mammalian GSK-3 (pdb entry 3ZDI, [25]) were 
defined: first, a hydrogen bond between the 6-amino-
group of the ligand and a water molecule near the hinge 
region, and second, a hydrogen bond between the car-
bonyl oxygen of the ligand and the side chain amino 
group of the canonical lysine (Lys108). The docking accu-
racy was defined as 200%, the “generate diverse solutions” 
option was enabled, and the “early termination” and “save 
lone pairs” features were disabled. 20 docking runs were 
performed for each ligand and the resulting poses ranked 
by score. Visualization of the poses was carried out with 
PyMol, vers. V0.99 [29]. All poses were visually inspected 
for plausibility and similarity to the ligand orientation in 
the template pdb 3ZDI [25].
Calculation of molecular parameters
The total polar surface area (TPSA) was calculated using 
the SwissADME interface [32] which utilizes the method 
developed by Ertl et al. [33].
Syntheses of test compounds
The new compounds belonging to series 2–4 were syn-
thesized via the synthesis route illustrated in Fig.  3, 
following published procedures for the synthesis of 
3,6-diamino-4-arylthieno[2,3-b]pyridine-5-carboni-
triles [25, 34–36]. In brief, aromatic aldehydes 5 were 
reacted with malonodinitrile 6 and cyanothioaceta-
mide 7 in ethanol in the presence of piperidine yielding 
the 2-thioxo-1,2-dihydropyridines 8. These intermedi-
ates proved to be unstable due to dimerization via oxi-
dation to disulfides and were therefore immediately 
processed as raw materials. Alkylation of 8 with the 
2-bromo-3′-chloroacetophenone 9 in DMF in the pres-
ence of potassium carbonate furnished the thioether 10, 
which was also not isolated but successively treated with 
Fig. 2 Orientation of thieno[2,3-b]pyridine 1 accommodated in the ATP-binding pocket of a PfGSK-3 homology model as predicted by docking 
experiments. Left: 3D-illustration (generated with PyMol, vers. V0.99 [29]). Right: 2D-sketch. Dashed black lines indicate hydrogen bonds. Colour 
code: blue, nitrogen; red, oxygen; yellow, sulfur; magenta, chlorine
Fig. 3 General procedure for preparation of thieno[2,3-b]pyridines 2–4. Reagents and conditions: (i) ethanol, piperidine, reflux, 3–6 h; (ii) 10% KOH, 
DMF, 30 min (iii) 10% KOH, DMF, 1–5 h
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further potassium hydroxide, resulting in a Thorpe-Zie-
gler ring closure reaction [37] which yielded the desired 
3,6-diamino-2-aroyl-4-arylthieno[2,3-b]pyridine-5-car-
bonitriles 2–4. Compound 3f which exhibits a vicinal 
dihydroxy motif was prepared from 3e by acid-catalyzed 
hydrolytic cleavage of the cyclic acetal function. Com-
pounds 4i and 4j were prepared from the Boc-protected 
precursor molecules 4f and 4g by cleavage with trifluoro-
acetic acid in dichloromethane.
The aromatic aldehydes 5 employed as starting mate-
rials for the syntheses of the new thieno[2,3-b]pyridines 
were prepared from either 2-chloro-4-hydroxybenzalde-
hyde and suitable alkyl halides by means of a Williamson 
ether synthesis procedure [38] or by nucleophilic substi-
tution of 2-chloro-4-fluorobenzaldehyde with appropri-
ate secondary amines [39].
Molecular structures, details of the syntheses and puri-
fication procedures as well as characterization data of all 
new products are described in the Additional file 1. The 
structural identity of new test compounds was confirmed 
by elemental analysis, IR, 1H NMR, 13C NMR and EI 
mass spectra. The purity of synthesized products used for 
biological evaluation was > 95% as determined by HPLC 
(100% AUC method).
Separation of enantiomers of compound 4b
The enantiomers of congener 4b were separated utilizing 
chiral column chromatography by a commercial separation 
service lab (Reach Separations, Nottingham, UK). The fol-
lowing separation conditions were employed: column Lux 
C1, 21.2 mm × 250 mm, 5 µm, flow rate 21 mL/min, detec-
tor wavelength 215 nm, injection volume 4000 µL contain-
ing 2  mg material, eluent isocratic MeOH/0.1% v/v  NH3. 
After chromatographic separation, combined fractions 
of the purified enantiomers were evaporated to near dry-
ness and transferred into final vessels with dichlorometh-
ane. The solvent was removed under a stream of nitrogen 
at 40 °C before being stored in a vacuum oven at 40 °C and 
5 mbar for 16 h to afford the separated enantiomers as yel-
low solids. The purity of the separated enantiomers was 
assessed by chiral HPLC. Up to now all efforts to generate 
single crystals suitable for assignment of the absolute con-
figuration of the separated enantiomers were unsuccessful.
Luciferase‑based viability screening for antiplasmodial 
activity [28]
For the luciferase-based viability assays, asexual eryth-
rocytic stages of transgenic NF54-luc P. falciparum were 
used. These parasites constitutively express high lucif-
erase levels. The parasites were cultured as described 
previously [25, 40]. Parasite cultures with parasitae-
mia of 0.5–1% were dispensed in triplicate into white 
96-well flat-bottom plates (each well contains 250  µL) 
(NUNC, Roskilde, Denmark) and incubated in the pres-
ence of 3  µM test compounds for 48  h (37  °C, 90%  N2, 
5%  CO2, and 5%  O2). 0.01% DMSO was included in the 
untreated infected RBC cultures as negative control, 
since the compounds stock initially was diluted in DMSO 
and each treatment well also contained 0.01% DMSO. 
Subsequently, 100  µL RPMI1640 media was removed 
from each well and a 100 µL volume of the Bright-Glo® 
substrate solution was added to each well. The resultant 
cleavage product of the reaction, light, was measured 
using a FLUOROSKAN FL luminometer (Thermo), to 
ascertain viable parasites. Untreated cultures were used 
as negative controls and to calculate the inhibition rate 
(0% inhibition of parasite growth). Experiments were per-
formed in triplicate and were repeated as a whole at least 
twice. Blasticidin (Sigma-Aldrich, St. Louis, MO, USA), 
used for selection of transfected parasites, was included 
as a positive control on each plate and gave > 90% inhi-
bition of parasite growth at concentration 2 µg/mL. Test 
compounds exhibiting satisfactorily inhibitory activity 
(in most cases > 25% inhibition of viability) were rated 
as actives. For active compounds  IC50 values were deter-
mined from dose–response curves. Calculation of para-
site growth inhibition, of the  IC50 values and statistical 
analysis were carried out using GraphPad Prism Version 
6.0b (GraphPad Software, Inc. San Diego, CA).
Cytotoxicity assay on HEK293 cells
HEK293T cells were seeded into a solid black flat bottom 
96 well plate (2.5 × 104  cells/well) in 200  μL Dulbecco 
Modified Eagle Medium (DMEM) supplemented with 
10% fetal bovine serum and 1% Pen/Strep (final concen-
tration of 100 U/mL Penicillin and 100 μg/mL Streptomy-
cin). Cells were incubated at 37 °C under 5%  CO2. After 
18  h the supernatant was removed and fresh DMEM 
containing serial dilutions of compounds was added. 
Compounds were solubilized in DMSO (final DMSO 
concentration in HEK293T culture was 0.5%.) Wells con-
taining 0.5% DMSO served as a negative control. Plates 
were incubated for further 48 h at 37 °C under 5%  CO2. 
To monitor cell viability the supernatant was removed 
and cells were incubated with 200  μL 10% PrestoBlue 
(Invitrogen) in PBS at 37  °C. After 30  min fluorescence 
(λex = 560 nm, λem = 590 nm) was measured in an EnVi-
sion multilable plate reader (Perkin Elmer, integration 
time 0.1 s/well). Data points were plotted into Graphpad 
Prism, normalized to the DMSO control and  IC50 values 
were calculated using nonlinear regression.
Production of recombinant PfGSK‑3 for Kinase Glo Plus 
assay
PfGSK-3 was cloned into pOPIN F expression vec-
tor [41] using ligation independent cloning (InFusion, 
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Takara Clontech). Expression vector was transformed 
into Escherichia coli C41 and expression of recombinant 
PfGSK3-6xHis was induced by incubation with 1  mM 
IPTG at 16 °C overnight. Recombinant protein was puri-
fied using immobilized metal affinity chromatography 
(elution with 250 mM imidazole) and size exclusion chro-
matography using Superdex200 and 75 16/60 columns 
(GE Healthcare).
Kinase‑Glo Plus Assay for inhibition of PfGSK‑3 
and HsGSK‑3
Kinase activity was measured using Kinase-Glo Plus 
Luminescent Kinase Assay (Promega). 20 ng recombinant 
GSK-3 were incubated for 30  min at 30  °C in the pres-
ence of 12  μM GS-1 peptide substrate (YRRAAVPPSP-
SLSRHSSPHQpSEDEEE, pS stands for phosphorylated 
serine, Biaffin GmbH & Co KG/proteinkinase.de) and 
6 μM ATP (ultra pure, Promega) in a total volume of 5 μL 
kinase reaction buffer (40 mM Tris/HCl pH 7.5; 20 mM 
 MgCl2; 0.1 mg/mL BSA). Kinase reaction mix was trans-
ferred to a solid white 384 well plate (NUNC, Thermo Sci-
entific) and kinase reaction was stopped by adding 5  μL 
RT Kinase-Glo reagent. After 10  min luminescence was 
measured in an EnVision multilabel plate reader (Perkin 
Elmer, integration time 0.5  s/well). To investigate inhibi-
tion of kinase activity compounds were directly added to 
the kinase reaction (DMSO concentration did not exceed 
1%). All samples were normalized to a negative control 
(reaction without kinase). Data points were plotted into 
Graphpad Prism, normalized to a DMSO control and  IC50 
values were calculated using nonlinear regression.
Radiometric assay for inhibition of PfGSK‑3
Recombinant GST-PfGSK-His was expressed in Rosetta 
2 (DE3) cells and purified on cobalt affinity resin as 
described previously [19]. Recombinant PfGSK-3 
(0.25  mg) was assayed with 48  µM GS-1 peptide as a 
substrate, in 25  mM Tris–HCl pH 7.5, 10  mM  MgCl2, 
1  mM EGTA, 1  mM EDTA, 0.5  mg/mL BSA, 5  mM 
DTT, 2 µg/mL heparin, in the presence of 15 µM [γ-32P] 
ATP (3000  Ci/mmol; 1  mCi/mL) (Perkin-Elmer, USA) 
in a final volume of 25 µL. After 30 min incubation at 
30 °C, 8 µL aliquots were spotted onto 1 × 1 cm pieces 
of P81 phosphocellulose paper (Reaction Biology, Mal-
vern, PA, USA) and 20  s later, the filters were washed 
five times (for at least 5  min each time) in a solution 
of 10  mL phosphoric acid/L water. Filters were rinsed 
in acetone and the dried filters and radioactivity was 
measured by Cherenkov counting. Blank values were 
subtracted and activities were expressed in percentage 
of the maximal activity, i.e. in the absence of inhibitors. 
Controls were performed with appropriate dilutions of 
dimethylsulfoxide.
Determination of kinetic solubility
Kinetic solubility indicates the solubility of the most 
rapidly precipitating form. Kinetic solubilities of 1 
and 4h were determined by laser nephelometry [42, 
43] using the NEPHELOstarPlus nephelometer (BMG 
LabTech, Ortenberg, Germany) and F-bottom trans-
parent 96-well plates. The instrument uses red laser 
light (635  nm, 80% intensity), which passes through 
the 96-well plate and which is scattered by turbid sus-
pensions. Each compound was measured six times at 
25  °C by preparing three independent stock solutions 
in concentrations of 5 to 10 mM in DMSO. From each 
stock solution two independent dilution series were 
prepared. Based on preliminary experiments, dilution 
concentrations were chosen such that at least five to six 
concentrations below and above the expected point of 
precipitation were recorded. To the 96-well plate con-
taining 198  µL aqueous phosphate buffer at pH 7.4, 
2 µL of each dilution sample in DMSO was added and 
shaken for 10 s. at 700 rpm (double orbital). Phosphate 
buffer pH 7.4 containing sodium chloride was prepared 
by dissolving disodium monohydrogen phosphate-
dodecahydrate (2.38  g), potassium dihydrogen phos-
phate (0.19  g) and sodium chloride (8.0  g) in water to 
a volume of 1000.0  mL. The pH was adjusted by add-
ing sulfuric acid. First, the plates were scanned without 
content to quantify the background, which was later 
subtracted from the obtained values of each individual 
well. As blank, 2  µL of neat DMSO was added to the 
phosphate buffer. Close to the point of precipitation, 
particle concentration can be assumed to be propor-
tional to the intensity of scattered light. The solubility 
curve is typically characterized by a distinct kick-off 
point. The concentration at the precipitation point cor-
responds to the intersection of two regression curves 
that result from separate analyses of dissolved and 
turbid samples. The calculations were performed with 
Microsoft Excel 2013.
Results
Considering the current resistance situation against 
approved anti-malarial drugs, new anti-plasmodial com-
pounds acting by hitherto unexploited mechanisms are 
urgently required. The study reported here was aimed 
at identifying structural options for the optimization of 
the known PfGSK-3 inhibitor 1. First, it was addressed 
which position in the molecule is suitable for the attach-
ment of side chains without losing the biological activity. 
Second, it was investigated whether the enantiomers of 
active compounds show differing activity, an assump-
tion deduced from the orientation of the inhibitors in the 
ATP binding pocket of PfGSK-3 predicted by molecu-
lar docking studies. In contrast to the target-oriented 
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screening which initially identified the thieno[2,3-b]pyri-
dines as PfGSK-3 inhibitors [25], in the present study a 
phenotypic assay was utilized with the aim of taking 
into account the membrane permeability of the inhibi-
tor molecules at an early stage of development. Based on 
the putative orientation of 1 in the ATP-binding site of 
PfGSK-3, the para position of the 4-phenyl substituent 
was selected as suitable attachment point for side chains. 
The compounds that were synthesized as novel conge-
ners carry at the indicated position either small substitu-
ents (halogen, methyl, hydroxy; series 2), alkoxy groups 
(series 3), or alkylamino substituents (series 4) (Fig.  1). 
The results of biological activity testing showed that a 
fluoro- or a chloro-substituent at the indicated para posi-
tion of the 4-phenyl ring were tolerated without loss of 
antiplasmodial activity (2a,b), whereas larger substituents 
(bromo or methyl, 2c,d) or a phenolic hydroxyl group 
(2e) decreased the antiparasitic properties. Organic sub-
stituents attached via an oxygen atom (series 3) gener-
ally led to diminished or completely lost antiplasmodial 
activity compared to prototype 1. Whether this observa-
tion is based on insufficient PfGSK-3 inhibitory activity 
by congeners 3 or because of poor permeation through 
erythrocyte and parasite membranes is not yet clear. The 
derivatives 4 in which monoamines (dimethylamino, 
pyrrolidino, piperidino or morpholino) are attached via 
the nitrogen atom were equipotent to 1. Evaluation of 
the separated enantiomers of the diethylamino derivate 
4b revealed that the (−) enantiomer completely failed 
to inhibit the parasites, while the (+) enantiomer led to 
improved inhibitory activity. The derivatives with the 
highest antiplasmodial activity in the series were repre-
sented by 4h (the dimethylaminoethyl derivative) and 4j 
(the piperazine derivative) which both contain an addi-
tional basic nitrogen in the attached side chain. A notice-
able exception is 4i, the only derivative bearing a primary 
basic aliphatic amino group in its side chain. Supposedly 
4i is unable to permeate through biological membranes 
due to its higher total polar surface area (TPSA) com-
pared to the closely related tertiary amine 4h (4i: TPSA 
163.3 Å2; 4h: TPSA 140.5 Å2).
Considering the antiplasmodial activity of all new com-
pounds reported here, congener 4h appeared as particu-
larly promising, exhibiting more than fourfold higher 
antiplasmodial potency versus the prototype compound 
1. In this respect it was of interest also to compare the 
kinase inhibitory activity and the solubility of optimized 
structure 4h and prototype 1 (Table 1). Both in a Kinase 
Glo Plus assay and in a radiometric assay, 1 and 4h pro-
duced submicromolar PfGSK-3 inhibition values. In both 
assay settings, 1 proved to be more potent than 4h, indi-
cating that the higher antiplasmodial activity of 4h might 
be the result of pharmacokinetic features like cellular 
uptake, efflux or metabolism. In the Kinase Glo Plus assay 
it was also shown that both 1 and 4h selectively inhibit 
the plasmodial versus the human GSK-3 orthologue with 
selectivity indices of 38 and 56, respectively. Although 
in the Kinase Glo Plus assay a lower ATP concentration 
(6 µM) was used than in the radiometric assay (15 µM), 
both 1 and 4h showed lower  IC50 values in the latter test 
system. While a conclusive explanation for this observa-
tion is not yet available, these results show that a compar-
ison of  IC50 values is pertinent only for data generated in 
the same test system. Viability tests with HEK293T cells 
versus plasmodial PfNF54-Luc erythrocytic stage cells 
revealed similar selectivity indices for 1 and 4h (SI = 6.4 
and 4.5, respectively). Determination of kinetic solubility 
Table 1 Results of biological evaluation
n.d. not determined
a for position of X, refer to Fig. 3. All structures are depicted in the Additional 
file 1
Code X–a % inhibition ± SD, 
PfNF54‑Luc at 3 µM
IC50 [µM], 
PfNF54‑Luc
1 [25] H– n.d. 5.5
2a Cl– 25.7 ± 3.5 6.2
2b F– 28.1 ± 3.3 6.1
2c Br– − 5.9 ± 1.3 n.d.
2d H3C– 12.4 ± 2.4 n.d.
2e HO– 0.2 ± 2.5 n.d.
3a H3CO– 33.2 ± 3.2 12.2
3b H5C2O– 14.5 ± 1.3 n.d.
3c C6H5–CH2–O– 12.8 ± 4.9 n.d.
3d 2-hydroxyethoxy– 25.6 ± 3.3 20.0
3e (2,2-dimethyl-1,3-diox-
olan-4-yl)methoxy–
− 11.7 ± 0.7 n.d.
3f 2,3-dihydroxypropoxy– 14.7 ± 1.8 n.d.
3g HO2C–CH2–O 31.3 ± 1.1 n.d.
4a Dimethylamino– 29.9 ± 5.6 5.7
(+)4b Diethylamino– 73.0 ± 1.2 1.1
(−)4b Diethylamino– − 24.4 ± 10.4 n.d.
4c Pyrrolidino– 33.0 ± 2.4 n.d.
4d Piperidino– 39.1 ± 1.1 5.0
4e Morpholino– 20.2 ± 4.8 n.d.
4f N-[2-(N-Boc-amino)ethyl)]-
N-(methyl)amino–
67.1 ± 2.7 2.5
4g N4-Boc-piperazino– 42.1 ± 2.9 3.8
4h N-(2-
dimethylaminoethyl)-N-
(methyl)amino–
99.9 ± 0.1 1.2
4i N-(2-aminoethyl)-N-
(methyl)amino-(as 
hydrochloride)
8.1 ± 3.3 n.d.
4j Piperazino-(as hydrochlo-
ride)
75.7 ± 1.5 1.5
BS Blasticidin 99.3 ± 0.7 n.d.
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by laser nephelometry [42, 43] showed that 4h displays 
more than threefold higher solubility  (S0 pH7.4 = 4.8  µM) 
compared to 1  (S0 pH7.4 = 1.5 µM) (Table 2).
The prototype compound 1 and the congeners 2–4 
display direct single bonds between the thieno[2,3-
b]pyridine and the phenyl substituent. Due to the 
ortho chloro-substitution of the latter the free rota-
tion around the biaryl linkage is restricted, resulting 
in axial chirality of the molecules (Fig.  4). It has been 
shown previously that a double substitution with chlo-
rine at both ortho positions leads to decreased PfGSK-3 
inhibition [44]. If the orientation as illustrated for 1 in 
Fig.  2 is realistic, only the  Ra-configured enantiomers 
can be accommodated to the ATP-binding site, because 
in this binding mode only the  Ra enantiomer is able to 
fit the ortho chloro substituent into place without caus-
ing a spatial clash. In consequence, the  Ra enantiomer 
should act as eutomer, displaying distinctly stronger 
PfGSK-3 inhibition and antiplasmodial activity. To test 
this assumption, the enantiomers of one representa-
tive (4b) of the 4-(alkylamino)phenyl series were sepa-
rated by chromatography on a chiral column. Indeed, 
only the enantiomer (+)-4b exhibited antiplasmodial 
activity and was much more potent as PfGSK-3 inhibi-
tor than the (−)-4b enantiomer (PfGSK-3  IC50-values in 
the Kinase Glo Plus assay: (+)-4b: 39.6 (35.1–45.5) µM; 
(−)-4b: > 100 µM). Both enantiomers did not show any 
inhibitory activity on the human GSK-3 orthologue 
(HsGSK-3  IC50-values in the Kinase Glo Plus assay: 
(+)-4b, (−)-4b: > 100 µM). So far, no single crystals of 
(+)-4b or (−)-4b could be generated, so that an unam-
biguous assignment of the configuration of these enan-
tiomers on the basis of X-ray structure analyses was 
impossible up to now.
Discussion
The 4-phenylthieno[2,3-b]pyridine 1 acts as antiplasmo-
dial agent presumably due to its selective PfGSK-3 inhibi-
tory activity. For optimization of potency and aqueous 
solubility molecular modifications of 1 compliant with 
its binding mode to the molecular target are necessary. 
In this regard, the para position at the 4-phenyl substitu-
ent in structure 1 was identified as suitable attachment 
point for side chains. However, the nature of the link 
between the side chain and the parent scaffold was cru-
cial for the properties of the derived congeners. Whereas 
alkoxy groups diminished the antiplasmodial activity, 
alkylamino chains tended to improve this property. As 
most promising result of the study, derivative 4h shows 
better aqueous solubility, retained PfGSK-3 inhibitory 
activity, improved antiplasmodial potency as well as 
selectivity versus human cells. However, further optimi-
zation in this class is necessary before the molecules may 
be assumed as lead structures for a preclinical develop-
ment. For this optimization process, the structure activ-
ity relationships disclosed here will be valuable. At the 
same time it was shown that the axial chirality displayed 
by the title compounds is of paramount importance for 
biological activity, an interesting feature which has been 
discussed for implications in drug development [45, 46], 
Table 2 Comparison of biological, structural and physicochemical properties of improved congener 4h and prototype 1 
a Kinase Glo Plus assay, mean value of three determinations, range given in brackets
b Radiometric assay, mean value of two determinations, range given in brackets
c HEK293T cell viability assay, mean value of six determinations, range given in brackets
d SI (selectivity index) = IC50 HEK293T/IC50 PfNF54-Luc
e Calculation of TPSA according to Ertl et al. [33] through Swiss ADME [32]
f Number of  sp3 hybridized carbons/total carbon count [26]
g Kinetic solubility determined by nephelometry in aqueous buffer (pH 7.4) in the presence of 1% DMSO [42, 43]; mean ± standard deviation
ID IC50 [µM], PfGSK‑3
a 
(Kinase Glo Plus)
IC50 [µM], HsGSK‑
3a (Kinase Glo 
Plus)
IC50 [µM], PfGSK‑
3b (radiometric)
IC50 [µM], 
PfNF54‑Luc
IC50 [µM], HEK
293Tc
SId TPSA [Å2]e Fsp3 f S0 p H 7.4, exp [µM]
g
1 0.24 (0.21–0.27) 9.08 (6.72–12.5) 0.151 (0.154–0.148) 5.5 35.2 (27.0–46.3) 6.4 134.0 0.00 1.5 ± 0.3
4h 0.72 (0.68–0.75) 40.2 (38.3–42.2) 0.184 (0.179–0.190) 1.2 5.56 (5.05–6.03) 4.6 140.5 0.19 4.8 ± 0.9
Fig. 4 Enantiomers of thieno[2,3-b]pyridine 4b. The rotation around 
the biaryl bond connecting the heterocycle and the 4-phenyl 
substituent is hindered by the ortho chloro substituent at the phenyl 
ring and the ortho cyano substituent in combination with the thieno 
anneland at the pyridine ring
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and has been exploited for enhancing the selectivity of 
kinase inhibitors [47]. In further optimization campaigns 
it has to be taken into account that not a racemate, but 
a separated and purified eutomer will be the drug com-
pound to be evaluated and developed.
Conclusions
The attachment of alkylamino side chains leads to the 
improvement of antiplasmodial activity and aqueous 
solubility of PfGSK-inhibitors belonging to the class of 
4-phenylthieno[2,3-b]pyridines. These molecules show 
axial chirality, a feature of high impact for biological activ-
ity. The findings can be exploited for the development 
of improved selective PfGSK-3 inhibitors. Such studies 
should comprise further broad modifications of the ami-
noalkyl side chains as well as separation and application of 
the active eutomer in biological test systems.
Additional file
Additional file 1. Molecular structures, details of the syntheses and purifi-
cation procedures as well as characterization data of all new products.
Abbreviations
ACT : artemisinin-based combination therapy; ADME: absorption, distribution, 
metabolism, excretion; AMA1: apical membrane antigen 1; AUC : area under 
the curve; DMEM: Dulbecco Modified Eagle Medium; DMF: N,N-dimethylfor-
mamide; DMSO: dimethyl sulfoxide; EI: electron impact; Fsp3: fraction of  sp3 
hybridized carbon atoms; GS: glycogen synthase; HEK: human embryonic 
kidney; HPLC: high performance liquid chromatography; HsGSK-3: Homo sapi-
ens glycogen synthase kinase-3; IC50: concentration for 50% inhibition; IPTG: 
isopropyl β-d-1-thiogalactopyranoside; IR: infra-red; NMR: nuclear magnetic 
resonance; PCR: polymerase chain reaction; PfGSK-3: Plasmodium falciparum 
glycogen synthase kinase-3; RBC: red blood cell; RPMI media: Roswell Park 
Memorial Institute media; TPSA: topological polar surface area; WHO: World 
Health Organization.
Authors’ contributions
AA, AM, AN, LP, MB, SIS designed studies, performed experiments and 
analysed the data. CD, RD, TWG, CK were involved in project administration, 
conceptualization and manuscript writing. All authors revised the paper. All 
authors read and approved the final manuscript.
Author details
1 Institut für Medizinische und Pharmazeutische Chemie, Technische Uni-
versität Braunschweig, Beethovenstraße 55, 38106 Braunschweig, Germany. 
2 Department of Microbiology and Molecular Genetics, IMRIC, The Kuvin 
Center for the Study of Infectious and Tropical Diseases, The Hebrew Uni-
versity-Hadassah Medical School, 91120 Jerusalem, Israel. 3 Centre for Struc-
tural Systems Biology, Deutsches Elektronen-Synchrotron, Notkestraße 85, 
22607 Hamburg, Germany. 4 Bernhard-Nocht Institute for Tropical Medicine, 
Bernhard-Nocht-Straße 74, 20359 Hamburg, Germany. 5 Biomedicine Discov-
ery Institute, Infection & Immunity Program, Department of Microbiology, 
Monash University, Clayton, VIC 3800, Australia. 6 Center of Pharmaceutical 
Engineering (PVZ), Technische Universität Braunschweig, Franz-Liszt-Straße 
35A, 38106 Braunschweig, Germany. 7 Present Address: Genomics Applications 
Laboratory, Core Research Facility, Faculty of Medicine, The Hebrew University-
Hadassah Medical School, 91120 Jerusalem, Israel. 8 Present Address: Centre 
for Chronic, Inflammatory and Infectious Diseases, School of Health and Bio-
medical Sciences, RMIT University, Bundoora, VIC 3083, Australia. 
Acknowledgements
The project was funded by the German Federal Ministry of Education and 
Research (BMBF BioDisc 7; 13GW0024) awarded to RD and CK. Support by the 
COST action CM1307 “Targeted chemotherapy towards diseases caused by 
endoparasites” (to CK) is gratefully acknowledged. AA is supported by a Jürgen 
Manchot-Stiftung fellowship. SIS is supported by a stipend of the Evangelis-
ches Studienwerk Villigst. We are grateful to Dr. Sophia Reindl, Dr. Christian 
Löw and Samuel Pazicky for advice on the purification of recombinant PfGSK3. 
We acknowledge support by the German Research Foundation and the Open 
Access Publication Funds of the Technische Universität Braunschweig (to CK)
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The data generated or analysed during this study are included in this pub-
lished article and its additional information files.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Funding
All sources of funding of the research are reported in the Acknowledgements 
section. The funding bodies had no role in the design of the studies, data col-
lection, analysis, interpretation of data and in writing of the manuscript.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 21 December 2018   Accepted: 12 March 2019
References
 1. WHO. World malaria report 2017. Geneva: World Health Organization; 
2017. http://www.who.int/malar ia/publi catio ns/world _malar ia_repor t/
en/. Accessed 12 July 2018.
 2. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, et al. 
Evidence of artemisinin-resistant malaria in western cambodia. N Engl J 
Med. 2008;359:2619–20.
 3. Daily JP. Malaria 2017: update on the clinical literature and management. 
Curr Infect Dis Rep. 2017;19:28.
 4. Phyo AP, von Seidlein L. Challenges to replace act as first-line drug. Malar 
J. 2017;16:296.
 5. Wells TN, Hooft van Huijsduijnen R, Van Voorhis WC. Malaria medicines: a 
glass half full? Nat Rev Drug Discov. 2015;14:424–42.
 6. Cabrera DG, Horatscheck A, Wilson CR, Basarab G, Eyermann CJ, 
Chibale K. Plasmodial kinase inhibitors: license to cure? J Med Chem. 
2018;61:8061–77.
 7. Canduri F, Perez PC, Caceres RA, de Azevedo WF Jr. Protein kinases 
as targets for antiparasitic chemotherapy drugs. Curr Drug Targets. 
2007;8:389–98.
 8. Doerig C, Abdi A, Bland N, Eschenlauer S, Dorin-Semblat D, Fennell C, 
et al. Malaria: targeting parasite and host cell kinomes. Biochim Biophys 
Acta. 2010;1804:604–12.
 9. Doerig C, Meijer L. Antimalarial drug discovery: targeting protein kinases. 
Expert Opin Ther Targets. 2007;11:279–90.
 10. Jirage D, Keenan SM, Waters NC. Exploring novel targets for antimalarial 
drug discovery: plasmodial protein kinases. Infect Disord Drug Targets. 
2010;10:134–46.
 11. Lucet IS, Tobin A, Drewry D, Wilks AF, Doerig C. Plasmodium kinases 
as targets for new-generation antimalarials. Future Med Chem. 
2012;4:2295–310.
 12. Rotella DP. Recent results in protein kinase inhibition for tropical diseases. 
Bioorg Med Chem Lett. 2012;22:6788–93.
Page 10 of 10Masch et al. Malar J           (2019) 18:89 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 13. Zhang VM, Chavchich M, Waters NC. Targeting protein kinases in the 
malaria parasite: update of an antimalarial drug target. Curr Top Med 
Chem. 2012;12:456–72.
 14. Okombo J, Chibale K. Recent updates in the discovery and develop-
ment of novel antimalarial drug candidates. Med Chem Commun. 
2018;9:437–53.
 15. Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, 
et al. Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium 
phosphatidylinositol 4-kinase. Sci Transl Med. 2017;9:eaad9735.
 16. Solyakov L, Halbert J, Alam MM, Semblat JP, Dorin-Semblat D, Reininger 
L, et al. Global kinomic and phospho-proteomic analyses of the human 
malaria parasite Plasmodium falciparum. Nat Commun. 2011;2:565.
 17. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic 
potential. Nat Rev Drug Discov. 2004;3:479–87.
 18. Saraswati AP, Ali Hussaini SM, Krishna NH, Babu BN, Kamal A. Glycogen 
synthase kinase-3 and its inhibitors: potential target for various therapeu-
tic conditions. Eur J Med Chem. 2018;144:843–58.
 19. Droucheau E, Primot A, Thomas V, Mattei D, Knockaert M, Richardson 
C, et al. Plasmodium falciparum glycogen synthase kinase-3: molecular 
model, expression, intracellular localisation and selective inhibitors. 
Biochim Biophys Acta. 2004;1697:181–96.
 20. Osolodkin DI, Zakharevich NV, Palyulin VA, Danilenko VN, Zefirov NS. Bio-
informatic analysis of glycogen synthase kinase 3: human versus parasite 
kinases. Parasitology. 2011;138:725–35.
 21. Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, et al. Crystal struc-
ture of glycogen synthase kinase 3 beta: structural basis for phosphate-
primed substrate specificity and autoinhibition. Cell. 2001;105:721–32.
 22. Prinz B, Harvey KL, Wilcke L, Ruch U, Engelberg K, Biller L, et al. Hierarchical 
phosphorylation of apical membrane antigen 1 is required for efficient 
red blood cell invasion by malaria parasites. Sci Rep. 2016;6:34479.
 23. Leost M, Schultz C, Link A, Wu YZ, Biernat J, Mandelkow EM, et al. Paul-
lones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-
dependent kinase 5/p25. Eur J Biochem. 2000;267:5983–94.
 24. Tolle N, Kunick C. Paullones as inhibitors of protein kinases. Curr Top Med 
Chem. 2011;11:1320–32.
 25. Fugel W, Oberholzer AE, Gschloessl B, Dzikowski R, Pressburger N, Preu 
L, et al. 3,6-diamino-4-(2-halophenyl)-2-benzoylthieno[2,3-b]pyridine-
5-carbonitriles are selective inhibitors of Plasmodium falciparum glycogen 
synthase kinase-3. J Med Chem. 2013;56:264–75.
 26. Lovering F, Bikker J, Humblet C. Escape from flatland: increasing 
saturation as an approach to improving clinical success. J Med Chem. 
2009;52:6752–6.
 27. Kruggel S, Lemcke T. Generation and evaluation of a homology model of 
pfgsk-3. Arch Pharm (Weinheim). 2009;342:327–32.
 28. Weidner T, Lucantoni L, Nasereddin A, Preu L, Jones PG, Dzikowski 
R, et al. Antiplasmodial dihetarylthioethers target the coenzyme a 
synthesis pathway in Plasmodium falciparum erythrocytic stages. Malar J. 
2017;16:192.
 29. DeLano W. The case for open-source software in drug discovery. Drug 
Discov Today. 2005;10:213–7.
 30. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and 
validation of a genetic algorithm for flexible docking. J Mol Biol. 
1997;267:727–48.
 31. Eldridge M, Murray C, Auton T, Paolini G, Mee R. Empirical scoring func-
tions: I. The development of a fast empirical scoring function to estimate 
the binding affinity of ligands in receptor complexes. J Comput Aid Mol 
Des. 1997;11:425–45.
 32. Molecular modelling group of the swiss institute of bioinformatics: Swiss 
adme; 2016. http://www.swiss adme.ch. Accessed 12 July 2018.
 33. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as 
a sum of fragment-based contributions and its application to the predic-
tion of drug transport properties. J Med Chem. 2000;43:3714–7.
 34. Litvinov V, Dotsenko V, Krivokolysko S. Thienopyridines: synthesis, proper-
ties and biological activity. Russ Chem Bull. 2005;54:864–904.
 35. Litvinov V, Dotsenko V, Krivokolysko S. The chemistry of thienopyridines. 
Adv Heterocycl Chem. 2007;93:117–78.
 36. Sharanin YA, Krivokolysko SG, Dyachenko VD. Cyclization reactions of 
nitriles. LIV. Synthesis and properties of 6-amino-4-aryl-3,5-dicyanopyri-
din-2(1H)-ones, the corresponding thiones, the pyridylidenemalononi-
triles and their hydrogenated analogs. Russ J Org Chem. 1994;30:620–6.
 37. Granik VG, Kadushkin AV, Liebscher J. Synthesis of amino derivatives of 
five-membered heterocycles by Thorpe-Ziegler cyclization. Adv Hetero-
cycl Chem. 1998;72:79–125.
 38. Luhr S, Vilches-Herrera M, Fierro A, Ramsay RR, Edmondson DE, Reyes-
Parada M, et al. 2-arylthiomorpholine derivatives as potent and selective 
monoamine oxidase b inhibitors. Bioorg Med Chem. 2010;18:1388–95.
 39. Yongpruksa N, Pandey S, Baker GA, Harmata M. Benzothiazines in organic 
synthesis. Synthesis of fluorescent 7-amino-2,1-benzothiazines. Org 
Biomol Chem. 2011;9:7979–82.
 40. Dzikowski R, Frank M, Deitsch K. Mutually exclusive expression of viru-
lence genes by malaria parasites is regulated independently of antigen 
production. PLoS Pathog. 2006;2:e22.
 41. Berrow NS, Alderton D, Sainsbury S, Nettleship J, Assenberg R, Rahman 
N, et al. A versatile ligation-independent cloning method suitable for 
high-throughput expression screening applications. Nucleic Acids Res. 
2007;35:e45.
 42. Hoelke B, Gieringer S, Arlt M, Saal C. Comparison of nephelometric, uv-
spectroscopic, and hplc methods for high-throughput determination of 
aqueous drug solubility in microtiter plates. Anal Chem. 2009;81:3165–72.
 43. Meine R, Becker W, Falke H, Preu L, Loaec N, Meijer L, et al. Indole-3-car-
bonitriles as dyrk1a inhibitors by fragment-based drug design. Molecules. 
2018;23:64.
 44. Brandt W.Neue Inhibitoren der Proteinkinasen PfGSK-3 und RET. Disserta-
tion Technische Universität Braunschweig; 2009.
 45. Laplante SR, Fader LD, Fandrick KR, Fandrick DR, Hucke O, Kemper R, et al. 
Assessing atropisomer axial chirality in drug discovery and development. 
J Med Chem. 2011;54:7005–22.
 46. LaPlante SR, Edwards PJ, Fader LD, Jakalian A, Hucke O. Revealing atropi-
somer axial chirality in drug discovery. ChemMedChem. 2011;6:505–13.
 47. Smith DE, Marquez I, Lokensgard ME, Rheingold AL, Hecht DA, Gustafson 
JL. Exploiting atropisomerism to increase the target selectivity of kinase 
inhibitors. Angew Chem Int Ed Engl. 2015;54:11754–9.
